Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968004 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
A Phase 3 study, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 224
- Enrollment target
NCT02968004 is a Phase 3 study that has completed, run by OPKO Health. The registered enrollment target is 224 participants.
The verdict
NCT02968004, a Phase 3 study, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 224 participants
- Enrollment target
Study Summary
This is an open-label, randomized, multicenter, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone deficiency.
Interventions
- DRUG Somatropin
- DRUG MOD-4023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2016-12 |
| Est. Completion | 2024-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02968004
The ClinicalTrials.gov registry entry for NCT02968004 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Somatropin is the first listed.
NCT02968004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02968004 about?
NCT02968004 is a clinical study titled "Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children". This is an open-label, randomized, multicenter, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone deficiency.
What is the current status of trial NCT02968004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 224 participants. The study started on 2016-12. Estimated completion is 2024-05.
What interventions are being tested in trial NCT02968004?
The interventions under investigation include: Somatropin (DRUG), MOD-4023 (DRUG).
Who is sponsoring clinical trial NCT02968004?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.